KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Paul K. Audhya Sells 3,125 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Paul K. Audhya sold 3,125 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $30,687.50. Following the completion of the transaction, the insider now directly owns 100,334 shares in the company, valued at approximately $985,279.88. This represents a 3.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

KalVista Pharmaceuticals Trading Down 5.7 %

Shares of KALV traded down $0.61 during trading hours on Friday, reaching $10.03. The stock had a trading volume of 447,802 shares, compared to its average volume of 309,626. The firm has a 50-day simple moving average of $8.84 and a 200 day simple moving average of $10.43. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.30 and a 12 month high of $15.50. The company has a market capitalization of $495.68 million, a price-to-earnings ratio of -2.76 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.01. On average, equities analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Frazier Life Sciences Management L.P. raised its stake in shares of KalVista Pharmaceuticals by 32.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company's stock worth $41,400,000 after purchasing an additional 1,200,000 shares during the last quarter. Woodline Partners LP lifted its position in shares of KalVista Pharmaceuticals by 111.8% during the fourth quarter. Woodline Partners LP now owns 1,288,401 shares of the specialty pharmaceutical company's stock valued at $10,913,000 after purchasing an additional 680,148 shares in the last quarter. Vestal Point Capital LP increased its stake in KalVista Pharmaceuticals by 19.3% in the 4th quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company's stock valued at $40,402,000 after buying an additional 770,000 shares during the last quarter. Tang Capital Management LLC increased its stake in KalVista Pharmaceuticals by 13.2% in the 4th quarter. Tang Capital Management LLC now owns 4,893,847 shares of the specialty pharmaceutical company's stock valued at $41,451,000 after buying an additional 572,300 shares during the last quarter. Finally, Stempoint Capital LP bought a new position in shares of KalVista Pharmaceuticals during the 4th quarter worth approximately $8,409,000.

Wall Street Analysts Forecast Growth

KALV has been the topic of a number of research analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. TD Cowen began coverage on KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $30.00 target price on the stock. Bank of America started coverage on KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They set a "buy" rating and a $22.00 target price for the company. HC Wainwright reissued a "buy" rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday, December 6th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).